Biostock Studio: Integrum has a monopoly situation in the U.S. market

Swedish Integrum AB has developed the only FDA approved method for treating amputees with bone-anchored prostheses. In an interview with Biostock, Rickard Brånemark, founder and Chairman of the Board at Integrum AB, describes the head start that the company has as being alone in the U.S. market for the next 3-5 years; a market which is worth billions of dollars annually.

After encountering a great deal of skepticism in the U.S. from his orthopaedic colleagues in the early 1990s, Rickard Brånemark’s research and the OPRA™ Implant System technology is now being embraced by leading hospitals and educational institutions.

Along with such prestigious institutions as Johns Hopkins and Walter Reed hospitals, the OPRA™ Implant System is also used exclusively by the U.S. Department of Defense for treating military amputees, who as young and active patients, enjoy the full benefits of this unique treatment. These benefits range from simply being able to wear a prosthesis all day, to be able to hold down a job or just avoid the pain associated with a traditional socket prosthesis.

To watch the full interview (in Swedish), click here.

Biostock is the Nordic region’s leading digital news and analysis service focussing on companies in the Life Science sector. Biostock owns extensive international reach through its exponentially growing network and partnerships